Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2

• Published in: Nature microbiology Vol. 7; no. 8; pp. 1180 - 1188
• Main Authors: Newman, Joseph, Thakur, Nazia, Peacock, Thomas P., Bialy, Dagmara, Elrefaey, Ahmed M. E., Bogaardt, Carlijn, Horton, Daniel L., Ho, Sammy, Kankeyan, Thivya, Carr, Christine, Hoschler, Katja, Barclay, Wendy S., Amirthalingam, Gayatri, Brown, Kevin E., Charleston, Bryan, Bailey, Dalan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2022; Nature Publishing Group
• Subjects: 13/1; 13/106; 631/250/590; 631/326/421; 631/326/596; Antibodies; Antiviral agents; Biomedical and Life Sciences; COVID-19; Cross-protection; Infectious Diseases; Life Sciences; Medical Microbiology; Microbiology; Older people; Parasitology; Severe acute respiratory syndrome coronavirus 2; Vaccines; Virology
• ISSN: 2058-5276; 2058-5276
• DOI: 10.1038/s41564-022-01163-3

SARS-CoV-2 variants may threaten the effectiveness of vaccines and antivirals to mitigate serious COVID-19 disease. This is of most concern in clinically vulnerable groups such as older adults. We analysed 72 sera samples from 37 individuals, aged 70–89 years, vaccinated with two doses of BNT162b2 (Pfizer–BioNTech) 3 weeks apart, for neutralizing antibody responses to wildtype SARS-CoV-2. Between 3 and 20 weeks after the second vaccine dose, neutralizing antibody titres fell 4.9-fold to a median titre of 21.3 (neutralization dose 80%), with 21.6% of individuals having no detectable neutralizing antibodies at the later time point. Next, we examined neutralization of 21 distinct SARS-CoV-2 variant spike proteins with these sera, and confirmed substantial antigenic escape, especially for the Omicron (B.1.1.529, BA.1/BA.2), Beta (B.1.351), Delta (B.1.617.2), Theta (P.3), C.1.2 and B.1.638 spike variants. By combining pseudotype neutralization with specific receptor-binding domain (RBD) enzyme-linked immunosorbent assays, we showed that changes to position 484 in the spike RBD were mainly responsible for SARS-CoV-2 neutralizing antibody escape. Nineteen sera from the same individuals boosted with a third dose of BNT162b2 contained higher neutralizing antibody titres, providing cross-protection against Omicron BA.1 and BA.2. Despite SARS-CoV-2 immunity waning over time in older adults, booster vaccines can elicit broad neutralizing antibodies against a large number of SARS-CoV-2 variants in this clinically vulnerable cohort. Analysis of the neutralizing antibody activity from sera of vaccinated individuals aged between 70 and 89 reveals a reduction of antibody titres against SARS-CoV-2 wildtype and antigenic escape of various variants of concern that links to specific mutations within the RBD. A booster vaccination helps increasing neutralizing antibody titres against the Omicron BA.1 and BA.2 variants in older adults.